Nappi D - Search Results

1

Elotuzumab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma: a multicenter, retrospective, real-world experience with 200 cases outside of controlled clinical trials.

Gentile M, Vigna E, Palmieri S, Galli M, Derudas D, Mina R, Della Pepa R, Zambello R, Martino EA, Bruzzese A, Mangiacavalli S, Zamagni E, Califano C, Musso M, Conticello C, Cerchione C, Mele G, Di Renzo N, Offidani M, Tarantini G, Casaluci GM, Rago A, Ria R, Uccello G, Barilà G, Palumbo G, Pompa A, Vincelli D, Brunori M, Accardi F, Amico V, Amendola A, Fontana R, Bongarzoni V, Rossini B, Cotzia E, Gozzetti A, Rizzi R, Sgherza N, Ferretti E, Bertuglia G, Nappi D, Petrucci MT, Di Raimondo F, Neri A, Morabito F, Musto P. Gentile M, et al. Among authors: nappi d. Haematologica. 2024 Jan 1;109(1):245-255. doi: 10.3324/haematol.2023.283251. Haematologica. 2024. PMID: 37439329 Free PMC article.

2

Daratumumab for the Management of Newly Diagnosed and Relapsed/Refractory Multiple Myeloma: Current and Emerging Treatments.

Offidani M, Corvatta L, Morè S, Nappi D, Martinelli G, Olivieri A, Cerchione C. Offidani M, et al. Among authors: nappi d. Front Oncol. 2021 Feb 17;10:624661. doi: 10.3389/fonc.2020.624661. eCollection 2020. Front Oncol. 2021. PMID: 33680948 Free PMC article. Review.

3

Pegfilgrastim for primary prophylaxis of febrile neutropenia in multiple myeloma.

Cerchione C, Nappi D, Martinelli G. Cerchione C, et al. Among authors: nappi d. Support Care Cancer. 2021 Nov;29(11):6973-6980. doi: 10.1007/s00520-021-06266-x. Epub 2021 May 14. Support Care Cancer. 2021. PMID: 33990881 Free PMC article. Review.

4

A case of efficacy of bendamustine in heavily pretreated multiple myeloma, refractory to pomalidomide.

Cerchione C, Nappi D, Di Perna M, Zacheo I, Migliaccio I, Salvatore D, Picardi M, Pane F, Catalano L. Cerchione C, et al. Among authors: nappi d. Clin Case Rep. 2017 Mar 8;5(4):505-507. doi: 10.1002/ccr3.773. eCollection 2017 Apr. Clin Case Rep. 2017. PMID: 28396778 Free PMC article.

5

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma.

Cerchione C, Nappi D, Di Perna M, Zacheo I, Pareto AE, Picardi M, Catalano L, Pane F. Cerchione C, et al. Among authors: nappi d. Case Rep Hematol. 2016;2016:6745286. doi: 10.1155/2016/6745286. Epub 2016 Oct 27. Case Rep Hematol. 2016. PMID: 27867671 Free PMC article.

6

Pegfilgrastim in Supportive Care of Hodgkin Lymphoma.

Cerchione C, Nappi D, Romano A, Martinelli G. Cerchione C, et al. Among authors: nappi d. Cancers (Basel). 2022 Aug 23;14(17):4063. doi: 10.3390/cancers14174063. Cancers (Basel). 2022. PMID: 36077600 Free PMC article.

7

[No title available]

[No authors listed] [No authors listed] PMID: 36164183

8

Lenalidomide at the dose of 25 mg every other day in patients affected by multiple myeloma and renal failure: a real-life experience.

Cerchione C, Nappi D, Pareto AE, Romano A, Martinelli V, Picardi M, Pane F, Catalano L. Cerchione C, et al. Among authors: nappi d. Anticancer Drugs. 2018 Apr;29(4):371-372. doi: 10.1097/CAD.0000000000000604. Anticancer Drugs. 2018. PMID: 29420336

9

Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.

Mondello P, Steiner N, Willenbacher W, Cerchione C, Nappi D, Mauro E, Ferrero S, Cuzzocrea S, Mian M. Mondello P, et al. Among authors: nappi d. Oncologist. 2018 Apr;23(4):454-460. doi: 10.1634/theoncologist.2017-0037. Epub 2018 Jan 9. Oncologist. 2018. PMID: 29317554 Free PMC article.

10

[No title available]

[No authors listed] [No authors listed] PMID: 36164181

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

33 results

Search Page